HALB is Running! Halberd Antibodies Shown To B
Post# of 102870
(Total Views: 47)
Posted On: 04/21/2021 12:44:51 PM
HALB is Running!
Halberd Antibodies Shown To Be Effective Against Multiple Covid-19 Mutations
8:00 am ET April 21, 2021 (Accesswire) Print
JACKSON CENTER, PA / ACCESSWIRE / April 21, 2021 / Halberd Corporation's (OTC PINK:HALB) two patent-pending monoclonal antibodies have demonstrated strong affinity and neutralizing capabilities against three of the identified SARS-CoV-2 mutations. The principal researcher, Dr. Shawn Chen, indicated that Halberd's two monoclonal antibodies have been successfully tested against the Q498Y, P499T and Q493K SARS-2 variants. Mouse testing is planned to confirm the laboratory tests and is scheduled to start as soon as the certified disease-free laboratory mice are secured.
William A. Hartman, Chairman, President & CEO of Halberd Corporation, said, "It is very exciting to realize that our antibodies against the Covid-19 Spike Protein are also effective against several of the current global Covid-19 mutations. We believe that Halberd's antibodies could be the solution for select Covid-19 mutations. Our work on antibodies continues in the search to develop even stronger bonding to the antigen's limited number of S-protein binding sites on the surface of the virion as well as attacking the larger nucleus (N-proteins) at the cell level. This could produce an incredibly strong antibody binding mechanism to the SARS-CoV-2 antigens and its variants, so that the antigens can be eliminated through the extracorporeal exposure to tuned radiofrequency energy."
Halberd Antibodies Shown To Be Effective Against Multiple Covid-19 Mutations
8:00 am ET April 21, 2021 (Accesswire) Print
JACKSON CENTER, PA / ACCESSWIRE / April 21, 2021 / Halberd Corporation's (OTC PINK:HALB) two patent-pending monoclonal antibodies have demonstrated strong affinity and neutralizing capabilities against three of the identified SARS-CoV-2 mutations. The principal researcher, Dr. Shawn Chen, indicated that Halberd's two monoclonal antibodies have been successfully tested against the Q498Y, P499T and Q493K SARS-2 variants. Mouse testing is planned to confirm the laboratory tests and is scheduled to start as soon as the certified disease-free laboratory mice are secured.
William A. Hartman, Chairman, President & CEO of Halberd Corporation, said, "It is very exciting to realize that our antibodies against the Covid-19 Spike Protein are also effective against several of the current global Covid-19 mutations. We believe that Halberd's antibodies could be the solution for select Covid-19 mutations. Our work on antibodies continues in the search to develop even stronger bonding to the antigen's limited number of S-protein binding sites on the surface of the virion as well as attacking the larger nucleus (N-proteins) at the cell level. This could produce an incredibly strong antibody binding mechanism to the SARS-CoV-2 antigens and its variants, so that the antigens can be eliminated through the extracorporeal exposure to tuned radiofrequency energy."
(0)
(0)Scroll down for more posts ▼